Bard PowerPort Blood Clot and Infection Claims 2026: DVT, Sepsis, the October Trial & Who Qualifies
Yes — Bard PowerPort lawsuits go well beyond catheter fractures. Blood-clot claims (deep vein thrombosis, pulmonary embolism) and infection claims (bloodstream infection, sepsis) sit at the center of MDL 3081, and the third bellwether trial — an infection case — is being tried October 13–30, 2026. Here is what those claims allege, where the litigation stands, and who qualifies.
Thousands of the 4,140 pending cases allege clots forming around a degrading catheter, and infections traveling from a cracked device into the bloodstream. For plain-English video explainers on related legal and money topics, the Problem Solved channel is a useful companion to this guide. Below: the medicine, the law, and the proof.
Key facts
- 4,140 cases pending in MDL 3081 (Oct. 1, 2026) — District of Arizona, Judge David G. Campbell, centralized August 2023.
- Two bellwethers decided: defense verdict in Cook (May 8, 2026); $40 million plaintiff verdict in Divelbliss (Sept. 4, 2026), a fracture case.
- The third bellwether (Lattanzio) is an infection/sepsis case, tried October 13–30, 2026, after the judge denied Bard's summary-judgment motion on September 25.
- The device: ChronoFlex AL catheter (polyurethane plus barium sulfate), FDA-cleared in 2006 for long-term vascular access and high-pressure "power injection" of contrast dye.
- No blanket recall: three limited FDA Class 2 recalls (2018, 2019, 2021) covering specific models and lots only.
What the Blood-Clot and Infection Claims Allege
The core allegation is material degradation: the ChronoFlex AL blend — polyurethane mixed with barium sulfate — can break down inside the body over years of implantation. A degraded catheter does two kinds of damage at once: its roughened, micro-cracked surface gives bacteria a place to colonize, while the same damaged surface disrupts blood flow and triggers clotting. Bard denies the defect theory, calling these known risks disclosed in the product's instructions — a dispute the bellwether trials are now testing.
The Two Injuries, in Plain Terms
Deep vein thrombosis (DVT) — a clot in a deep vein, usually in the arm, shoulder, or chest near the catheter — is the signature clot injury; if part breaks loose to the lungs it becomes a pulmonary embolism, which can be fatal. Sepsis — the body's overwhelming, life-threatening response to a bloodstream infection — is the signature infection injury, escalating from fever and chills to septic shock within hours. Both frequently force emergency port removal and prolonged hospitalization.
Where the Litigation Stands in October 2026
Cases are coordinated as MDL No. 3081 — multidistrict litigation, a federal procedure grouping similar cases for shared discovery while each plaintiff keeps an individual claim. The docket grew from 3,187 actions on May 1 to 4,140 on October 1, 2026. Bellwether trials — test cases tried first — have split: a defense verdict in Cook, then the $40 million Divelbliss verdict. Two more are set for December 1, 2026 and February 2, 2027. For the verdict-by-verdict picture, see our Bard PowerPort October 2026 status update.
Why the Third Bellwether Trial Matters
The October 13–30 trial (Lattanzio) is the first infection case to reach a jury — and its path there matters. Bard moved to dismiss it as time-barred; on September 25, 2026, Judge Campbell denied the motion. A plaintiff verdict would prove juries award damages on this injury theory, as Divelbliss did for fracture claims; a defense verdict would send the opposite signal. Either way, the outcome shapes the settlement discussions expected to intensify once the trial run ends in early 2027.
Who Benefits From This — and Who Does Not
Who benefits. Patients with a Bard PowerPort (or related Bard port: Powerflow, SlimPort, X-Port, MRI Ports, Groshong, Titanium, Vaccess CT) who later developed a DVT, pulmonary embolism, or bloodstream infection and sepsis. Families of patients who died after a port-related clot or infection may have wrongful-death claims. And patients whose port was surgically removed because of clotting or infection hold the documented harm these cases are built on — see our guide to the five documents that decide a claim's value.
Who does not. People whose port worked without complication — without an injury there is no claim. Patients whose clot or infection has a clearly documented unrelated cause, since causation is proven individually. And anyone treating the $40 million Divelbliss verdict as a price list: one jury's award in a fracture case is not a settlement schedule. Compensation varies widely by case.
The Records That Make or Break Your Claim
These claims live or die on paperwork: the implant card or operative report showing which Bard model was placed and when; imaging (ultrasound, CT, X-ray) documenting the clot or catheter position; blood-culture results and hospital records for the infection; records of blood-thinner or antibiotic treatment; and the removal operative report. Keep a simple timeline — implant date, first symptoms, diagnosis, treatments. Document each link: device, injury, treatment. For contrast with the fracture cases, read our explainer on catheter fracture and migration qualification.
Deadlines: Why Waiting Is Dangerous
Every state sets its own filing deadline — the statute of limitations, the legal time limit for bringing a claim — often two to three years from the injury or its discovery. Bard's failed bid to dismiss Lattanzio as time-barred proves deadlines are fought over, not automatic. Evidence degrades too: records get archived, memories fade. If you suspect a port-related clot or infection, get a legal review now rather than waiting for the litigation to resolve.
Frequently asked questions
Who benefits most from the blood-clot and infection claims?
Patients with a Bard-manufactured port who suffered DVT, pulmonary embolism, or bloodstream infection and sepsis — and families pursuing wrongful-death claims.
Who does not qualify for a Bard PowerPort claim?
People whose device caused no injury — without an injury there is no claim. Claims need a Bard-manufactured port, and records pointing to a clearly unrelated cause will undermine causation.
How do I start a Bard PowerPort claim?
Gather implant records, imaging, and hospital records; write a timeline from implantation through treatment; then get a free case review from a firm handling MDL 3081 cases — most work on contingency.
Is there a Bard PowerPort settlement yet?
No global settlement has been announced. The litigation is in the bellwether phase, with serious talks expected after the trial run ends in early 2027. Compensation varies widely by case.
Has the Bard PowerPort been recalled?
No blanket recall exists. The FDA lists three limited Class 2 recalls (2018, 2019, 2021) covering specific models and lots.
Is this a class action?
No — it is a multidistrict litigation (MDL). Cases share discovery, but each plaintiff must prove their own injuries; one verdict does not decide the others.
This article provides general information about ongoing litigation. It is not legal advice and does not create an attorney-client relationship. Deadlines and rules vary by state — consult a qualified attorney about your situation.